Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody

February 8, 2021

Nieto, G., Jara, R., Watterson, D., et al.

Nature 2021, vol: 11 doi: 10.1038/s41598-021-82833-w

Abstract

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with potential therapeutic applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of Nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.

View Publication

Topics: Monolith, MST, Tycho, Virology, Publications

Previous Article
Quantifying the interaction of phosphite with ABC transporters: MicroScale Thermophoresis and a novel his-tag labeling approach
Quantifying the interaction of phosphite with ABC transporters: MicroScale Thermophoresis and a novel his-tag labeling approach

Up next
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

Ready to characterize your most challenging interactions?

Discover tools to measure binding affinity

Learn more